Results 131 to 140 of about 1,783,252 (315)
Aggregate, EarlyView.This study develops a supramolecular photosensitizer (SeVB⊃PQ) by combining SeVB with a P. gingivalis‐targeting peptide. SeVB⊃PQ selectively binds P. gingivalis, boosts ROS generation under irradiation, disrupts ATP synthesis, restores microbial balance, reduces inflammation, and promotes alveolar bone regeneration, offering a promising platform for ...
Rui Ding +7 more
wiley +1 more source
THE ABNORMAL HUMAN HEMOGLOBINS
Medicine, 1956 H A, ITANO, W R, BERGREN, P, STURGEON
openaire +2 more sources
Aggregate, EarlyView.This study addresses AMPs' clinical application challenges by enhancing stability via molecular assembly. Pba* shows high antibacterial activity, biocompatibility, and low toxicity, paving the way for antimicrobial materials. ABSTRACT Natural antimicrobial peptides (AMPs) encounter significant challenges in transitioning to clinical application ...
Xu Guo +7 more
wiley +1 more source
International Journal of Nanomedicine, 2018 Kaitlin Graham, Evan Unger NuvOx Pharma, Tucson, AZ, USA Abstract: Hypoxia exists to some degree in most solid tumors due to inadequate oxygen delivery of the abnormal vasculature which cannot meet the demands of the rapidly proliferating cancer cells.
Graham K, Unger E
doaj
Advanced Intelligent Systems, EarlyView.This study introduces a framework to monolithically 3D print highly bioinspired hands, composed of soft and stiff segments, using cost‐effective desktop printers. A magnetic resonance imaging‐informed approach replicates key anatomical features, such as collateral ligaments and volar plates, enabling enhanced functionality and human‐like behavior. This
Gianni Stano +5 more
wiley +1 more source
The First Case of Hemoglobin J-Guantanamo Reported During HbA1c Measurement by High-Performance Liquid Chromatography at Moroccan Military Hospital Mohammed V. [PDF]
Cureus, 2023 Ouzzif Z, El Moussadeq G, El Maataoui A.
europepmc +1 more source
Primary Structure of the Hemoglobins from the Greater Kudu Antelope Tragelaphus strepsiceros) [PDF]
, 1985 Braunitzer, G. +2 more
core +1 more source
American Journal of Hematology, EarlyView.ABSTRACT Iptacopan is a first‐in‐class, oral, selective inhibitor of complement factor B that has demonstrated positive efficacy across several complement‐driven diseases. Here we evaluate the efficacy and safety of iptacopan monotherapy in adult patients with primary immune thrombocytopenia (ITP) and primary cold agglutinin disease (CAD). We performed
Alexander Röth +13 more
wiley +1 more source